AGP Executive Report
Last update: 7 hours agoObesity Drug Showdown: An indirect comparison links tirzepatide 15 mg to greater weight loss than semaglutide 7.2 mg in SURMOUNT-5, with GI side effects the main discontinuation driver. RSV Prevention Update: Clesrovimab is shown to remain effective and well-tolerated when repeated in infants at risk across a second RSV season. Depression Care Access: New discussion highlights accelerated TMS (SAINT) as a faster path toward remission for treatment-resistant depression, plus MRI-targeting considerations. Dermatology Pipeline: EADV coverage spotlights ritlecitinib repigmentation in nonsegmental vitiligo and deeper-control data across psoriasis/HS/AD programs. Public Health Alerts: Pennsylvania reports a fifth measles death as cases near 1,000; Nepal confirms 131 Japanese encephalitis cases with most unvaccinated. Policy & Competition: AHA backs a hospital challenge to Lilly’s 340B policy, while regulators weigh hospital consolidation and post-acute care differences in Medicare Advantage. Healthcare Ops: Kerala’s health minister denies medicine shortages in government hospitals, blaming pharma and media claims. Genomics for Kids: GeneDx rolls out “Easy Order” to simplify pediatric genomic testing workflows for AAP use.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
